低蛋白饮食联合RAAS抑制剂在CKD管理中的作用
该综述汇总实验与临床研究,探讨低蛋白饮食(LPD)联合RAAS抑制剂对CKD进展的潜在叠加效应。实验模型显示联合治疗可显著减少蛋白尿和肾小球硬化,但缺乏高质量干预试验。目前证据不足以推荐联合方案,作者支持开展大规模随机临床试验。
要点
- LPD与RAAS抑制剂在实验模型中均延缓CKD进展并减少蛋白尿。
- 联合治疗在动物模型中显著减少蛋白尿和肾小球硬化。
- 尚无高质量干预试验验证联合策略,证据不足以推荐。
核心结论
- 实验研究支持LPD联合RAAS抑制剂可能通过减少高滤过、尿毒症毒素、酸负荷和磷负荷发挥叠加肾脏保护作用。
- 目前缺乏高质量干预试验,证据不足以推荐联合LPD与RAAS抑制剂延缓CKD进展。
- 作者主张开展大规模随机临床试验研究该联合策略。
研究设计与样本
- 综述汇总实验和临床研究,评估LPD与RAAS抑制剂联合对CKD进展的潜在叠加作用。
主要发现
- 在不同动物CKD模型中,RAAS抑制剂联合LPD可显著减少蛋白尿和肾小球硬化。
- LPD可降低肾小球高滤过、尿毒症毒素生成,以及酸、磷和钠负荷。
- RAAS活性通过增加肾小球毛细血管滤过压和促纤维化分子(如TGF-β)合成促进肾损伤。
临床怎么用
- 目前不推荐常规联合LPD与RAAS抑制剂延缓CKD进展,需等待高质量随机临床试验结果。
局限性
- 缺乏高质量干预试验研究LPD联合RAAS抑制剂对CKD进展的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In experimental studies a low-protein diet (LPD) and renin-angiotensin-aldosterone system (RAAS) inhibitors are both reported to slow the progression of chronic kidney disease (CKD) and reduce proteinuria. RAAS activity contributes to increased blood pressure, fluid retention, and positive sodium balance, but also to kidney damage by enhancing glomerular capillary filtration pressure and synthesis of profibrotic molecules such as transforming growth factor β. It has been well established that an LPD decreases glomerular hyperfiltration and the generation of uremic toxins, as well as the burden of acid load, phosphorus, and sodium. In different animal CKD models, a significant reduction in proteinuria and glomerulosclerosis has been achieved when an RAAS inhibitor and LPD were combined. To date, high-quality intervention trials investigating this combined strategy are lacking. We summarize the experimental and clinical studies that have examined a potential additive action of these therapies on CKD progression. We outline potential mechanisms of action and additive efficacy of an LPD and RAAS inhibitors in CKD, with a particular emphasis on phosphate levels, uremic toxin production, acid load, and salt intake. Finally, although the evidence is inadequate to recommend combining RAAS inhibitors and an LPD to slow the progression of CKD, we provide a perspective to support a large-scale randomized clinical trial to study this combination.
引用
- Koppe L, Fouque D. The Role for Protein Restriction in Addition to Renin-Angiotensin-Aldosterone System Inhibitors in the Management of CKD. Am J Kidney Dis. 2018. PMID: 30149957. doi:10.1053/j.ajkd.2018.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。